Strut Health Pricing History and Trajectory: What Patients Actually Pay

What Is Strut Health and How Does Its Cash-Pay Model Work?

Strut Health operates as a direct-to-consumer telehealth platform. Patients complete an online intake form, a licensed prescriber reviews the case asynchronously, and medications ship directly if the prescriber approves. No insurance is accepted and no brick-and-mortar visit is required.

The cash-pay model has a predictable pricing logic: the company absorbs the consultation cost into the medication margin, which means the headline "free visit" is funded by per-unit drug pricing. That structure is common in telehealth but worth understanding before you compare Strut against a traditional pharmacy plus a $25 GoodRx coupon.

The Asynchronous Prescribing Model

Unlike synchronous telemedicine (live video), Strut uses asynchronous review. A prescriber reads your intake, may send follow-up questions by message, and approves or declines within one to two business days. The FDA does not regulate the telehealth delivery model itself, but it does regulate the compounded drugs Strut dispenses, particularly under 21 U.S.C. 503A and 503B compounding pharmacy rules. Patients can review FDA compounding guidance at fda.gov.

Is the Prescribing Compliant?

Strut's prescribers are licensed in the states they serve. The platform lists its affiliated pharmacy partners, which are expected to operate under state board oversight. LegitScript, a third-party pharmacy verification organization, certifies telehealth pharmacies on a voluntary basis. As of this review, Strut's compounding pharmacy partners have not appeared on LegitScript's verified pharmacy list, which is a data point worth noting even if absence from that list does not itself indicate illegal operation.

Strut Health Pricing History: 2020 Through 2025

Prices have not been static. Tracking the trajectory requires separating the intake fee from the drug cost, because those two levers moved independently.

2020 to 2021: Launch-Era Pricing

Strut launched with aggressive acquisition pricing. Compounded finasteride 1 mg/mL topical or oral formulations were available for approximately $25 to $30 per month. The implicit goal was customer acquisition, a standard playbook for DTC health brands in that period. Sildenafil and tadalafil compounds entered the catalog at prices between $1.50 and $3.00 per dose, competing directly with Ro, Hims, and Rex MD on cost.

2022: Supply Chain Pressure and Reformulation

The 2022 period brought compounding ingredient shortages, particularly for APIs (active pharmaceutical ingredients) used in hair loss compounds. Finasteride API prices rose after global supply chain disruptions. Strut's monthly subscription price for hair loss products moved into the $35 to $45 range during this window. Some customers reported price changes on renewal without explicit advance notice, a complaint category that surfaces repeatedly in BBB informal reviews.

The FDA issued multiple shortage notices for finasteride API intermediates during 2022 and 2023, which you can verify through the FDA drug shortage database.

2023 to 2024: Peptide Expansion and Premium Tier

Strut added peptide therapies, specifically BPC-157 and sermorelin, to its catalog in 2023. These products carry higher price points, typically $150 to $300 per month, consistent with the broader compounded peptide market. The FDA has taken enforcement action against compounded BPC-157, noting it does not appear on the FDA's list of bulk drug substances that may be used in compounding under 503A or 503B. The relevant FDA guidance is available at fda.gov.

This is a material compliance issue. Patients ordering compounded BPC-157 from any telehealth platform, including Strut, should understand that the FDA has questioned the legal basis for its compounding. That uncertainty does not make the drug dangerous per se, but it does introduce regulatory risk for the dispensing pharmacy.

2025: Current Price Points

As of mid-2025, Strut's advertised prices are approximately:

| Product | Monthly Cost (Approx.) | |---|---| | Oral finasteride 1 mg (compounded) | $35, $45 | | Topical finasteride/minoxidil combo | $45, $55 | | Oral minoxidil (compounded) | $30, $40 | | Sildenafil 20 mg x 10 doses | $25, $40 | | Tadalafil 5 mg daily | $35, $50 | | Sermorelin (injectable, 30-day) | $150, $220 |

Prices vary by state, formulation strength, and active promotions. First-month discounts of 20 to 30 percent are common.

How Strut's Prices Compare to Key Competitors

The table below places Strut in context against four major telehealth competitors across two high-volume product categories. Prices reflect publicly listed or independently verified cash-pay pricing as of Q2 2025 and are intended as a directional comparison, not a purchasing guarantee.

| Brand | Compounded Finasteride/Mo | Compounded Tadalafil 5 mg/Mo | Consultation Fee | |---|---|---|---| | Strut Health | $35, $55 | $35, $50 | $0 | | Hims | $30, $55 (brand varies) | $40, $65 | $0 | | Ro | $35, $60 | $45, $70 | $0 | | Rex MD | $30, $45 | $30, $45 | $0 | | LifeMD/GetRoman | $35, $55 | $45, $65 | $0 |

Strut sits in the middle of this competitive range. It is not the cheapest option for finasteride, and it is not the most expensive. The differentiating claim Strut makes is formulary depth, specifically the combination products (finasteride plus minoxidil in a single topical) that some competitors do not offer.

Why Combination Topicals Command a Premium

A 2019 randomized controlled trial published in Dermatology and Therapy (N=153) found that a combined topical finasteride and minoxidil formulation produced significantly greater hair count improvement than minoxidil alone at 24 weeks (see PubMed). Strut markets this evidence to justify the higher price of its combination products. The logic is sound if the compounded formulation matches the concentrations used in the trial, but compounded products are not FDA-approved and bioavailability data on specific compounded combinations is limited.

Is Strut Health Legit?

Strut Health is a real company with real licensed prescribers and real pharmacy partners. The question of legitimacy is better asked as a series of narrower questions.

Licensing and Regulatory Standing

Strut's prescribers hold state licenses verifiable through state medical board databases. The affiliated compounding pharmacies are state-licensed and PCAB (Pharmacy Compounding Accreditation Board) accreditation status varies. Patients can verify any pharmacy's accreditation at nabp.pharmacy, an NABP resource. Strut is not FDA-approved as a drug manufacturer because it does not manufacture drugs. It functions as a telehealth front-end for licensed pharmacies.

BBB Profile and Complaint Patterns

The Better Business Bureau profile for Strut Health shows a pattern of complaints concentrated in two areas: shipping delays (packages arriving two to three weeks after expected delivery) and auto-renewal billing where patients report not receiving adequate notice before charges. The BBB does not accredit Strut Health as of mid-2025. A BBB rating is not a regulatory endorsement, but the complaint pattern is a real operational signal.

The FDA's MedWatch program allows patients to report adverse events from any medication, including compounded drugs. Patients experiencing unexpected side effects can file at fda.gov/safety/medwatch.

Clinical Safety of the Medications Themselves

Finasteride 1 mg (Propecia) is FDA-approved for male androgenetic alopecia. A Cochrane systematic review covering 26 randomized trials concluded that finasteride at 1 mg/day increases hair count and patient-assessed outcomes versus placebo with a well-characterized side-effect profile (Cochrane Library). Strut prescribes finasteride in doses consistent with FDA-approved labeling.

Sildenafil and tadalafil are FDA-approved for erectile dysfunction. The approved labeling, including contraindications with nitrate medications, applies regardless of whether the drug is dispensed through a telehealth platform or a retail pharmacy. The full FDA label for tadalafil is available at accessdata.fda.gov.

Strut Health Complaints: A Category-by-Category Breakdown

Complaints about Strut follow recognizable patterns seen across DTC telehealth. Knowing the categories helps you decide whether they are disqualifying.

Billing and Auto-Renewal Issues

The most common complaint type involves subscription auto-renewal. Patients report being charged for a second or third shipment without receiving a reminder email. This is partly a business model issue: DTC telehealth brands depend on subscription revenue and cancellation friction is sometimes built in. The FTC's guidelines on negative option billing, last updated in 2023, require clear disclosure of auto-renewal terms before purchase. Strut's checkout flow discloses auto-renewal in the terms, but patients report the disclosure is not prominently featured.

If you subscribe to Strut or any telehealth platform, set a calendar reminder for day 20 of your first month so you have time to cancel before the next billing cycle.

Shipping and Compounding Lead Times

Compounded medications cannot be manufactured in bulk and stored. Each batch is made to order, which means lead times of seven to fourteen days are standard across the compounded telehealth industry. Strut's shipping complaints largely reflect patients expecting retail-pharmacy speed from a compounding pipeline. Some complaints describe delays exceeding three weeks, which is outside the typical compounding window and suggests intermittent operational bottlenecks.

Prescriber Responsiveness

Asynchronous prescribing means response times vary. Most patients report receiving a prescriber decision within one to two business days. A smaller share report waiting four to five days, which is a longer delay than the platform advertises. This matters clinically if you are running out of an existing medication.

What Drives Price Changes at Compounding Telehealth Platforms?

Price trajectory at any compounding telehealth brand is driven by four factors: API commodity pricing, pharmacy labor costs, platform marketing spend, and regulatory compliance costs.

API Commodity Pricing

Finasteride API is a generic commodity traded globally. When Indian or Chinese API manufacturers face production disruptions or FDA import alerts, domestic compounding pharmacies pay more per gram. That cost passes to the patient. The FDA maintains a drug shortage list that provides leading-indicator data on which APIs are under pressure.

Regulatory Compliance Costs

The FDA's increased scrutiny of 503A compounding pharmacies since 2021 has raised compliance costs across the industry. Pharmacies facing FDA inspections must invest in documentation, cleanroom upgrades, and quality systems. Those costs do not disappear. They get distributed across the per-unit drug price. A 2022 study in the American Journal of Health-System Pharmacy found that compliance with USP <797> sterile compounding standards added an estimated 8 to 15 percent to per-unit costs at small compounding pharmacies (PubMed).

Platform Marketing and Acquisition Costs

DTC telehealth brands spend heavily on paid search and social media. Customer acquisition costs in this space reportedly run $80 to $150 per new patient based on industry benchmarks. Those costs are recovered through subscription margins over the patient lifetime. When acquisition costs rise (as they did with iOS privacy changes in 2021 that reduced ad targeting efficiency), platforms have two options: raise prices or accept lower margins. Most raised prices modestly.

Competition and Price Floors

Generic sildenafil at a retail pharmacy with a GoodRx coupon costs approximately $10 to $20 for 10 tablets of 20 mg. That price floor constrains how much any telehealth platform can charge for compounded sildenafil before patients defect to traditional pharmacy channels. This competitive pressure has kept ED medication pricing relatively stable even as hair-loss product prices drifted upward.

Red Flags to Watch Before Subscribing

Not every concern about Strut rises to the level of a disqualifying factor, but the following warrant attention.

Compounded BPC-157 availability. As noted above, the FDA has questioned the legal basis for compounding BPC-157. Any platform offering it is operating in a gray zone, and the regulatory situation could change rapidly.

No LegitScript certification. Voluntary certification is not required, but its absence means an independent third party has not audited the platform's prescribing and dispensing practices.

Auto-renewal terms. Read the cancellation policy before you enter a credit card. The FTC's updated Negative Option Rule, effective 2024, requires clearer cancellation mechanisms for subscription services. If cancellation requires a phone call rather than a single online click, that is a consumer-experience red flag.

State availability gaps. Strut does not operate in all 50 states. Prescribers licensed in one state cannot prescribe to patients in another state except in limited interstate compact circumstances. Verify your state is fully served before completing intake.

Who Gets the Best Value From Strut Health?

Strut offers reasonable value for patients who meet a specific profile: men seeking compounded combination hair-loss products (finasteride plus minoxidil topical) that are harder to source through retail pharmacy channels, who prefer asynchronous prescribing over synchronous video visits, and who are comfortable managing a subscription billing relationship.

For straightforward generic finasteride 1 mg or generic tadalafil 5 mg daily, a retail pharmacy with a GoodRx or Mark Cuban Cost Plus Drug Company coupon may be substantially cheaper. Cost Plus Drugs lists generic finasteride 1 mg at under $10 per month as of 2025. If the only appeal is cost, traditional pharmacy wins.

The value proposition for Strut is narrowest for peptide therapies given the regulatory uncertainty around compounded BPC-157 and the comparatively high monthly cost.

Clinical Takeaways for Prospective Patients

A clinical comparison published in JAMA Dermatology in 2018 confirmed that the combination of finasteride and minoxidil produces additive benefit over either agent alone in androgenetic alopecia, supporting the use of combination formulations (JAMA Network). If you need that combination and cannot source it conveniently at a retail pharmacy, a platform like Strut may provide a real clinical convenience benefit.

The Endocrine Society's 2021 clinical practice guideline on male hypogonadism states: "Clinicians should counsel patients that compounded testosterone preparations lack FDA approval and are subject to less rigorous quality standards than FDA-approved products." The same principle applies to all compounded drugs dispensed through telehealth platforms, not only testosterone. The guideline is available at endocrine.org.

Before subscribing to any compounded telehealth service, confirm the dispensing pharmacy's PCAB accreditation status, review the auto-renewal cancellation terms, and verify that your specific medication is on the FDA's list of permissible 503A bulk drug substances.